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Abstract Medium-size-artery vasculitides do occur in
childhood and manifest, in the main, as polyarteritis nodosa
(PAN), cutaneous PAN and Kawasaki disease. Of these,
PAN is the most serious, with high morbidity and not
inconsequential mortality rates. New classification criteria
for PAN have been validated that will have value in
epidemiological studies and clinical trials. Renal involve-
mentiscommonandrecenttherapeuticadvancesmayresultin
improved treatment options. Cutaneous PAN is a milder
disease characterised by periodic exacerbations and often
associated with streptococcal infection. There is controversy
as to whether this is a separate entity or part of the systemic
PAN spectrum. Kawasaki disease is an acute self-limiting
systemic vasculitis, the second commonest vasculitis in
childhood and the commonest cause of childhood-acquired
heart disease. Renal manifestations occur and include tubu-
lointerstitial nephritis and renal failure. An infectious trigger
and a genetic predisposition seem likely. Intravenous immu-
noglobulin (IV-Ig) and aspirin are effective therapeutically,
but in resistant cases, either steroid or infliximab have a role.
Greater understanding of the pathogenetic mechanisms
involved in these three types of vasculitis and better long-
term follow-up data will lead to improved therapy and
prediction of prognosis.
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Introduction
Vasculitis can be defined as inflammation and necrosis of
blood vessels. By common usage, the term predominantly
refers to arterial disease, and this interpretation will be used in
this educational review. Although more common in adults
than in children, vasculitis does occur in childhood and may
present as a primary disorder or be a feature of some other
systemic disease. Various attempts at classification and
nomenclature of vasculitides in both adults and children have
beenpublished [1–9]. Most have focussed on vessel size as a
useful distinguishing feature, resulting in vasculitis being
categorised as affecting large vessels, medium-size vessels
and small vessels. The large-vessel category in childhood
refers primarily to Takayasu disease; the medium-size-vessel
category includes polyarteritis nodosa (PAN), Kawasaki
disease (KD) and cutaneous polyarteritis nodosa (CPAN);
the small-vessel category is usually subdivided into granu-
lomatous disease [Wegener’s granulomatosis (WG) and
Churg-Strauss syndrome] and nongranulomatous disorders
[microscopic polyangiitis (MPA), the leukocytoclastic vas-
culitides such as Henoch-Schönlein purpura (HSP), isolated
cutaneous leukocytoclastic vasculitis and hypocomplemente-
mic urticarial vasculitis]. There are, in addition, vasculitides
affecting various-sized vessels, including Behçet disease,
vasculitis associated with infection, vasculitis secondary to
connective tissue diseases, isolated vasculitis of the central
nervous system, Cogan’s syndrome and others [5]. This
educational review focuses on medium-size-vessel vasculitis,
specifically, PAN, KD and CPAN.
Polyarteritis nodosa
This is a necrotising vasculitis associated with aneurysmal
nodules along the walls of medium-sized muscular arteries
and is the condition classically described by Kussmaul and
Maierin1866[10]. Despite some overlap with smaller-vessel
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DOI 10.1007/s00467-009-1336-1disease, PAN appears to be a distinct entity and, in adults in
Europe and the United States, appears to have an estimated
annual incidence of 2.0–9.0/million [11]. Although compar-
atively rare in childhood, it is the most common form of
systemic vasculitis after HSP and KD [12, 13]. However, the
data are difficult to interpret, as the incidence in various
reports differs widely depending on which criteria are used to
classify patients as PAN [11]. Peak age of onset in childhood
is 7–11 years, with often a male preponderance.
Classification
Until recently, no specific criteria for classifying a child as
having PAN existed. Most paediatricians either used the
American College of Rheumatology (ACR) criteria [14]o r
the Chapel Hill Consensus Conference on nomenclature
description [3]. To overcome these shortcomings, an
International Paediatric Consensus Conference was held in
Vienna in 2005. This resulted in a new proposal for the
general classification of childhood vasculitides and pro-
posals for classification criteria for several important
categories of childhood vasculitis, including PAN [5, 15]
(Table 1).
The classification criteria for childhood PAN were
biopsy of a small or medium artery showing necrotising
vasculitis or suggestive arteriography as a mandatory
criterion, plus at least two of the following: skin involve-
ment, myalgia or muscle tenderness, hypertension, mono-
or polyneuropathy, abnormal urine analysis and/or renal
impairment, testicular pain or tenderness and signs or
symptoms suggestive of vasculitis of any other organ
system [5]. It was proposed that these criteria would be
subjected to a validation process. TheseandtheACRcriteria
were found to perform suboptimally, and modifications of the
criteria were proposed. These new criteria for PAN are as
follows: histopathological evidence of necrotising vasculitis
in medium- or small-sized arteries or angiographic abnormal-
ity (aneurysm,stenosis orocclusion)as a mandatory criterion;
plus one of the following five: skin involvement, myalgia or
muscle tenderness, hypertension, peripheral neuropathy, renal
involvement [16]. Sensitivity and specificity were 73% and
100% respectively (Table 2).
It is, however, important to appreciate that classification
criteria are not diagnostic criteria, and meeting classifica-
tion criteria is not equivalent to making a diagnosis in an
individual patient [17]. A diagnosis is made by considering
all clinical features in a patient, only some of which may be
classification criteria [17]. In this context, it has been
considered that the establishment of diagnostic criteria for
childhood PAN would also be of value, and although attempts
have been made to do so [18], this is currently under review.
Clinical manifestations
The main clinical features of PAN are malaise, fever, weight
loss, skin rash, myalgia, abdominal pain and arthropathy [6,
18–25]. In addition, ischaemic heart and testicular pain; renal
manifestations such as haematuria, proteinuria and hyperten-
sion [23, 26, 27]; neurologic features such as focal defects,
hemiplegia, visual loss, mononeuritis multiplex; and organic
psychosis [28–30] may be present. Skin lesions are variable,
and may masquerade as those of HSP or multiform erythema
but can also be necrotic and associated with peripheral
gangrene [31, 32]. Lesions sometimes mimic pyoderma
gangrenosum. Livido reticularis is also a characteristic feature,
and occasionally subcutaneous nodules overlying affected
Table 1 Proposed classification of childhood vasculitis (adapted from
Ozen et al. [5] with permission)
I. Predominantly large vessel vasculitis
Takayasu arteritis
II. Predominantly medium-sized-vessel vasculitis
Childhood systemic polyarteritis nodosa (PAN)
Cutaneous PAN
Kawasaki disease (KD)
III. Predominantly small-vessel vasculitis
A. Granulomatous
Wegener’s granulomatosis
Churg Strauss syndrome
B. Nongranulomatous
Microscopic polyangiitis
Henoch-Schönlein purpura
Isolated cutaneous leukocyclastic vasculitis
Hypocomplementemic urticarial vasculitis
IV. Other vasculitides
Behçet’s disease
Vasculitis secondary to infection (including hepatitis-B-associated
PAN), malignancy and drugs, including hypersensitivity vasculitis
Vasculitis associated with connective tissue disease
Isolated vasculitis of the central nervous system
Cogan’s syndrome
Unclassified
Table 2 Criteria for classifying polyarteritis nodosa (PN) (adapted
from Ozen et al. [16] with permission)
Histological evidence of necrotizing vasculitis in medium or small sized
arteries or angiographic abnormalities (aneurysms, stenoses or
occlusion) as a mandatory criterion, plus one out of the following five:
1 Skin involvement
2 Myalgia or muscle tenderness
3 Hypertension
4 Peripheral neuropathy
5 Renal involvement
1642 Pediatr Nephrol (2010) 25:1641–1652arteries are present [31, 32]. Systemic involvement is variable,
but the skin, the musculoskeletal system, the kidneys and the
gastrointestinal tract are most prominently affected, with
cardiac, neurological and respiratory manifestations occurring
less frequently [9, 18, 19, 21–23, 33, 34]. In some patients,
rupture of arterial aneurysms can cause retroperitoneal and
peritoneal bleeding, with perirenal haematomata being a
recognised manifestation of this phenomenon [35]. This
feature has been noted a number of times in Turkey where
it has occurred in patients with the well-recognised association
of PAN and familial Mediterranean fever [36, 37]. However,
clinical manifestations (and investigation findings) can be
very confusing, with certainly in the early phase and
sometimes the late phase of the illness absence of conclusive
diagnostic evidence [38].
Differential diagnosis
Differential diagnosis includes other primary vasculitides
(HSP, WG, MPA, KD); connective tissue diseases (juvenile
rheumatoid arthritis, dermatomyositis, lupus, mixed con-
nective tissue disease); sarcoidosis; Behçet’s disease, viral
infections, subacute bacterial endocarditis and lymphoma
and other malignancies.
Diagnostic laboratory and radiological investigation
Anaemia, polymorphonuclear leukocytosis, thrombocytosis,
increased erythrocyte sedimentation rate (ESR) and C-
reactive protein (CRP) are usually present in the active phase
of the disease. Platelets are hyperaggregable, and there are
circulating immune complexes [39]. Positive hepatitis B
serology in children is unusual in association with PAN but
can occur [40]. However, the association between hepatitis B
infection and PAN is well recognised in adults [41].
Antineutrophil cytoplasmic antibodies (ANCA) are not
thought to play a major part in the causality of PAN, but
there are reports demonstrating their presence in some adults
[42, 43] and children with PAN [44, 45]. The presence of
cytoplasmic ANCA (C-ANCA) with antibodies to proteinase
3 in a patient suspected of having PAN makes it mandatory
to eliminate Wegener’s granulomatosis as a diagnosis.
Likewise, a significant titre of perinuclear ANCA (P-ANCA)
with antibodies to myeloperoxidase would necessitate steps
to ensure that MPA was not the diagnosis. Biopsy material
can prove diagnostically important, especially if an affected
area or lesion of the skin, muscle or other tissue is available.
The characteristic histopathological changes of PAN are
fibrinoid necrosis of the walls of medium or small arteries,
with a marked inflammatory response within or surrounding
the vessel [46]( F i g .1). However, absence of such changes
would not exclude the diagnosis, as the vasculitic features
are variable and affected tissue may not have been sampled
at the time. Renal biopsy is usually not helpful and carries a
greater risk than usual of bleeding and the formation of
arteriovenous fistulae [32, 47].
Indirect evidence of the presence of medium-size artery
vasculitis affecting the renal arteries may be obtained by
demonstrating patchy areas within the renal parenchyma of
decreased isotope uptake on Tc-99m dimercaptosuccinic
acid (DMSA) scanning of the kidneys [34, 48]. However,
the most valuable investigative procedure is renal and
hepatic ± mesenteric angiography. Radiological findings
include aneurysms, segmental narrowing and variations in
the calibre of arteries, together with pruning of the
peripheral vascular tree [26, 33, 49–51] (Fig. 2). Magnetic
resonance angiography (MRA) usually fails to detect
microaneurysms, although it can demonstrate large intra-
and extrarenal aneurysms and stenoses/occlusions of the
renal arteries or their branches and areas of ischaemia and
infarction [52]. However, MRA overestimates vascular
stenotic lesions [53, 54]. Computed tomography angiogra-
phy (CTA) may also reveal larger aneurysms and occlusive
lesions and demonstrate areas of cortical ischaemia and
infarction but at the expense of high ionising radiation
exposure, which is a concern in childhood [52, 54, 55].
Although not a routine investigative procedure, the recently
developed measurements of circulating endothelial micro-
particles and circulating endothelial cells may prove helpful in
demonstrating the presence of active vasculitic disease as well
as throwing light on the mechanisms involved [56–62].
Furthermore, measurement of circulating endothelial progen-
itor cells may be helpful in pointing to evidence of a repair
process being under way in the recovery phase of disease [61,
63]. However, this may not be so clear cut in children and
further work is necessary to clarify their role [64, 65].
Fig. 1 Polyarteritis nodosa (PAN), acute phase. High-power view of
skin biopsy from a 4-year-old boy with PAN. Biopsy shows a
neutrophilic vasculitis affecting medium and small arteries in the deep
dermis and subcutis. There is also an associated lobular panniculitis
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The aetiology of PAN remains unclear, but there are data to
support roles for hepatitis B [40, 41] and reports of a higher
frequency of exposure to parvovirus B19 and cytomegalo-
virus in PAN patients compared with control populations
[66, 67]. HIV has also been implicated [68], and PAN-like
illnesses have been reported in association with cancers and
haematological malignancies [69]. However, in childhood,
associations between PAN and these infections or other
conditions are rare. Evidence has emerged suggesting that
bacterial superantigens may play a role in some cases [70].
Occasional reports link PAN to immunisation, but the
evidence is not convincing. It seems likely that the immu-
nological processes involved are similar to those in other
systemic vasculitides and include immune complexes, com-
plement, possibly autoantibodies, cell adhesion molecules,
cytokines, growth factors, chemokines, neutrophils and T
cells [71, 72]. Recent evidence that rituximab can be
successful therapeutically suggests that B cells also have a
pathogenetic role [24]. There may be genetically predispos-
ing factors that may make individuals vulnerable to PAN and
other vasculitides. An example of this is the link with
familial Mediterranean fever [36, 37]. There are three reports
of PAN occurring in siblings that add weight to this
hypothesis, but there are no detailed genetic studies [73–75].
Treatment
Formanyyears,PANtreatmenthasinvolvedadministrationof
high-dose steroid with an additional cytotoxic agent, such as
cyclophosphamide, to induce remission [76–82]. In most
patients, it is appropriate to treat aggressively. However, in
those presenting with mild disease, verging on CPAN, steroid
alone is sometimes recommended. Cyclophosphamide might
be given orally in a dose of 2 mg/kg per day for 2–3m o n t h s
or by pulsed monthly intravenous injections for up to
6 months or for shorter periods in children if remission is
achieved. Aspirin has also been prescribed empirically as an
antiplatelet agent [24]. Once remission is achieved, mainte-
nance therapy with daily or alternate-day low-dose prednis-
olone and oral azathioprine is frequently used for up to
18 months [80]. Other maintenance agents include metho-
trexate, mycophenolate mofetil and cyclosporin A [82].
Adjunctive plasma exchange can be used in life-threatening
situations [83, 84], and more recently, successful treatment
with biologic agents such as infliximab or rituximab has been
reported for those unresponsive to conventional therapy [24,
80–82, 85–88]. Treatment response can be assessed using a
modified Birmingham Vasculitis Activity Score [82].
Outcome
PAN, unlike some other vasculitides such as WG, appears to
bea condition inwhich permanent remission can beachieved.
Relapses can occur, but despite these, a realpossibility ofcure
can be anticipated. However, if treatment is delayed or
inadequate, life-threatening complications can occur due to
the vasculitic process. Severe complications, especially
infections, can occur from treatment with immunosuppressive
drugs [77, 81, 89, 90]. In comparison with the almost 100%
mortality rate in the presteroid era [91], mortality rates as low
as 1.1% were reported in a recent retrospective multicentre
analysis [40]. However, this may not truly reflect mortality in
circumstances of severe disease because 30% of patients in
that series were considered to have CPAN. A mortality rate
of 10% was recently recorded from a major tertiary referral
centre seeing predominantly children with aggressive ad-
vanced disease [92]. Late morbidity can occur years after
childhood PAN from chronic vascular injury, resulting in
premature atherosclerosis [93]( F i g .3). This remains a cause
for concern and an area of ongoing research.
Cutaneous polyarteritis nodosa
CPAN is a form of vasculitis affecting small- and medium-
sizedvessels limitedtotheskin[94]. It is characterised by the
presence of fever; subcutaneous nodular, painful, nonpurpu-
ric lesions with or without livedo reticularis occurring
Fig. 2 A renal angiogram from a 6-year-old girl with polyarteritis
nodosa (PAN) demonstrating florid aneurysmal and nonaneurysmal
changes. There are large and small aneurysms, perfusion defects,
arterial cutoff and lack of crossing of peripheral renal arteries (From
Brogan et al. [33] with permission)
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involvement (except for myalgia, arthralgia and nonerosive
arthritis) [94, 95]. It is well recognised in childhood, and
there are a number of reports in the literature [40, 96–98]. In
a recent international survey of childhood vasculitis, approx-
imately one third of children identified as having PAN were
categorised as CPAN [40]. The clinical course is charac-
terised by periodic exacerbations and remissions that may
persist for many years and occasionally throughout child-
hood. Skin biopsy shows necrotizing nongranulomatous
small- and medium-sized vessel vasculitis, tests for ANCA
are usually negative and the condition is often associated
with serological or microbiological evidence of streptococcal
infection [99, 100]. Nonrecurring CPAN has been observed
in neonates born to mothers with chronic CPAN [94, 101,
102]. There has been much discussion as to whether the
condition should be classed as a separate entity or as a part
of the spectrum of PAN [94]. In the main, the condition
remains localized to the skin [94, 103], although a proportion
of cases appear to evolve into full-blown PAN, and clinicians
need to be mindful of this possibility [104]. The distinction is
difficult, and patients with more extensive clinical involve-
ment or lack of response to standard treatment may need to
be further evaluated and possibly treated as if they had PAN
[105]. There are some investigators who feel that their data
support the view that CPAN does not progress to PAN [106].
Treatment
The condition may respond to nonsteroidal anti-inflammatory
drugs [96, 107] but can achieve remission with moderate
doses of oral steroids [94]. When streptococcal infection is
implicated, penicillin may be effective [100, 108]. Some
clinicians recommend continuing prophylactic penicillin
throughout childhood, as relapses are common and occur in
up to 25% of cases in association with further streptococcal
infections [100, 109]. When there is a lack of response to
standard treatment or concerns about possible steroid toxicity,
intravenous immunoglobulin (IV-Ig) has been successfully
used [110]. Some success has also been reported with
methotrexate [111], colchicine and dapsone [112], cyclophos-
phamide [98], pentoxifylline [113] and chloroquine [114].
Outcome
Many, but not all, patients experience a persistence of
cutaneous lesions through childhood, but it is uncommon
for the condition to progress to PAN [94]. However, it is
mandatory for such patients to remain under surveillance to
detect any evidence of developing systemic disease that
would be an indication for intensification of treatment
along the lines of that required for PAN.
Kawasaki disease
KD is an acute self-limiting systemic vasculitis predomi-
nantly affecting young children. Distribution is worldwide,
with a male preponderance, an ethnic bias towards Asian
children, seasonality and occasional epidemics [115–119].
It is the second commonest vasculitic illness of childhood
(HSP being the commonest) and the commonest cause of
acquired heart disease in children in the UK and USA
[120–122]. The incidence in Japan is 138/100,000 [123]i n
children younger than 5 years, whereas in the United States,
it is 17.1 [124] and in the UK 8.1 [125].
Clinical manifestations
The principal clinical features are fever persisting for
5 days or more, peripheral extremity changes (reddening of
the palms and soles, indurative oedema and subsequent
desquamation), a polymorphous exanthema, bilateral con-
junctival injection/congestion, lips and oral cavity changes
(reddening/cracking of lips, strawberry tongue, oral and
pharyngeal injection) and cervical lymphadenopathy (acute
nonpurulent). For the diagnosis to be established according to
the Diagnostic Guidelines of the Japan Kawasaki Disease
Research Committee, five of six criteria should be present
[126]. The North American recommendations for the
diagnosis are similar, except that fever is a mandatory
criterion and four of the remaining five criteria are required
to establish the diagnosis [127]. If coronary artery aneurysms
are present, fewer features may be necessary for diagnostic
Fig. 3 Late vasculopathy associated with polyarteritis nodosa (PAN).
High-power view of histology taken from a heminephrectomy
specimen (duplex system and recurrent infection) from a 4-year-old
girl with classic severe PAN of 18 months duration who was in
remission on treatment. Very abnormal medium-sized arteries are
present, consistent with healed vasculitis with internal elastic lamina
rupture, fibrosis and intimal thickening but no active vasculitis
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modifications, were adopted as classification criteria for
KD, but perineal desquamation was added to the criteria at
the Vienna Consensus Conference on the Classification of
Childhood Vasculitides [5] describing changes in extremities.
Cardiovascular features are the most important manifesta-
tions of the condition, with widespread vasculitis affecting
predominantly medium-size muscular arteries, especially the
coronary arteries. Coronary artery involvement occurs in 15–
25% of untreated cases, with additional cardiac features in a
significant proportion of these, including pericardial effusion,
electrocardiographic abnormalities, pericarditis, myocarditis,
valvular incompetence, cardiac failure and myocardial
infarction [128, 129]. Vascular damage to the major limb
arteries, renal and other visceral vessels and the aorta can be
demonstrated [129, 130]. Other systemic involvement can
occur, including in the gastrointestinal tract [131], the
hepatobiliary tract with hydrops of the gall bladder being
well recognised [132], the respiratory tract [133], the central
nervous system with seizures and meningeal features [134],
deafness [135], arthropathy [136] and renal involvement.
Renal manifestations include pyuria, proteinuria, tubular
disturbances, tubulointerstitial nephritis and renal failure
[137–147]. The mechanism of the renal impairment is
unclear, and there is some evidence suggesting that IV-Ig
used in treatment might play a part [148]. Another clinical
sign that may be relatively specific to KD is the development
of erythema and induration at sites of Bacillus Calmette-
Guérin (BCG) inoculations [149]. The mechanism of this is
thought to be cross-reactivity of T cells in KD between
specific epitopes of mycobacterial and human heat-shock
proteins [150].
Diagnostic laboratory and other investigations
Polymorphonuclear leukocytosis, thrombocythemia and
increased ESR and CRP are characteristic findings in the
acute phase of KD [116, 118]. Two-dimensional echocar-
diography is the means of identifying coronary artery
involvement acutely and monitoring changes long term
[116, 118]. Coronary angiography has a role, especially in
the presence of giant coronary artery aneurysms or in
circumstances when stenotic lesions are suspected, but
provides little information about the microvasculature [118,
151]. Dobutamine stress echocardiography has a role in
follow-up evaluation [152]. Spiral CTA [153] and MRA
[154] have been advocated, but the former is associated
with significant radiation and the latter has limited
resolution. Coronary arteriography has an important role
for delineating detailed anatomical injury, particularly for
children with giant coronary artery aneurysms (>8 mm), in
which stenoses adjacent to the inlet/outlet of the aneurysms
are a concern. It is important to note that coronary
arteriography should be delayed until at least 6 months
after disease onset, as there could be a risk of myocardial
infarction if performed in children with ongoing severe
coronary artery inflammation [118].
Aetiopathogenesis
The aetiology of KD is unknown, but it is thought that
some ubiquitous infectious agent produces an abnormal
immunological response in a genetically susceptible
individual, which results in the characteristic clinical
picture. A number of polymorphisms have been identified
that appear to be linked to disease susceptibility or the
risk of coronary artery aneurysms [155, 156]. A genome-
wide association study identified five genes with functional
relationships to inflammation, apoptosis and cardiovascular
pathology [157]. In addition, another study has reported an
association of the functional polymorphism of the inositol
1,4,5-triphosphate 3-kinase C (ITPKC) gene with immune
activation of KD [158]. ITPKC acts as a negative regulator
of T-cell activation and may contribute to immune hyper-
reactivity in KD. Furthermore, there is some evidence that a
bacterial toxin causes KD [155]. This hypothesis is based
on clinical and immunological similarities between KD and
staphylococcal or streptococcal toxin-mediated illnesses
and the recent observations that some children with KD
seroconvert with IgM antibodies against a number of
bacterial superantigens [159]. However, an alternative view
is that the immune response in KD is oligoclonal (as with
conventional antigens) and that IgA plasma cells play a
central role [160].
Treatment
Treatment of KD with aspirin and IV-Ig has been shown to
reduce the occurrence of coronary artery aneurysms [118,
161]. IV-Ig is recommended within 10 days of disease onset
but is also appropriate for late presenters with active disease
[116, 118]. IV-Ig resistance occurs in up to 20% of cases
[118]. In such circumstances, corticosteroids have been
advocated, but there are conflicting data from various
randomised controlled trials as to their effectiveness [162–
166]. From these data it is suggestive that perhaps cortico-
steroids need to be given over a more protracted period to
achieve benefit, as the major studies used a single IV dose of
methylprednisolone. All studies have been complicated by
the need to evaluate steroid treatment along with IV-Ig, as it
has not been considered ethically appropriate to undertake a
trial directly comparing steroid with IV-Ig. Anecdotally,
however, there are reports of steroid being beneficial when
IV-Ig has failed and also of the effective use of steroid in
patients who have refused IV-Ig on the basis of being
Jehovah’s Witnesses [116, 167, 168]. Additionally, there is
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lone plus gammaglobulin may have a role as initial treatment
in high-risk KD patients [169]. More recently, there are
reports of the beneficial effects of infliximab in the treatment
of IV-Ig-resistant KD [169–171].
In the convalescent phase, if aneurysms persist, anti-
platelet therapy in the form of low-dose aspirin should be
continued long term until the aneurysms resolve [116]. In
the presence of giant aneurysms (>8 mm), warfarin is
recommended in addition to aspirin [118]. Some patients
may require coronary angioplasty or a revascularisation
procedure should ischemic symptoms arise or evidence of
obstruction occur [129].
Outcome
The outlook for KD patients is generally good. The acute
mortality rate in Japan is 1.14 [172, 173]. Angiographic
resolution 1–2 years after disease onset has been observed in
50–70% of vessels with coronary aneurysms [174]. About
20% of patients who develop coronary artery aneurysms
during the acute stage of the disease will develop coronary
artery stenoses [174], and the risk is greater with large (giant)
aneurysms [175]. However, there are data suggesting that,
despite seeming recovery, there are long-term cardiovascular
sequelae that persist into adult life and that may have
important implications. Impaired endothelial function in
peripheral [176, 177] and coronary arteries [178] has been
reported, as have increased carotid media thickness and
arterial stiffness [179]. Perhaps more important than these
studies of novel surrogate markers for subclinical athero-
sclerosis is the long-term epidemiological data from Japan.
In the seventh look at the long-term outcomes of a cohort of
6,576 patients with KD enrolled between 1982 and 2004, the
mortality rate for patients without cardiac sequelae in the
acute phase of the disease and for female patients with
sequelae did not differ from the normal population [172].
The mortality rate of male patients with cardiac sequelae
was, however, 2.4 times higher than the normal population
[172]. Epidemiological studies from Japan also have
demonstrated that late sequelae, especially in patients with
large aneurysms, include myocardial ischaemia with a
frequency of 3% within 4 years after the disease onset [118].
Conclusion
Vasculitis affecting medium-size vessels does occur in
childhood. The distinction from other conditions is often
difficult, especially in the context of PAN, although it is
usually possible to categorise the disorders into clinical-
pathological entities. Further studies are needed on the
aetiopathogenetic mechanisms involved in the development
of these vasculitides that might hopefully lead to more
focussed therapeutic approaches. Although current treat-
ment has made a major impact on disease activity control,
there remains a need for more randomised controlled trials,
especially using newer biologic agents, to establish their
roles in therapy. Finally, more follow-up studies are needed
to establish the long-term implications of developing these
conditions in childhood.
Multiple-choice questions:
(Answers appear following the reference list)
1. Which of the following is true in relation to childhood
PAN?
a. Crescentic glomerulonephritis is a well-recognised
complication
b. There is often a discrepancy between the ESR and
the CRP results
c. Cytoplasmic ANCA is usually detectable
d. Livido reticularis is a characteristic feature
2. In childhood PAN, which of the following statements is
correct?
a. Most cases have an infective aetiology
b. Renal and hepatic angiography is a valuable
investigative tool
c. The aorta is frequently affected
d. Cyclophosphamide is contraindicated because of
side effects
3. In relation to cutaneous childhood PAN, which of the
following is true?
a. Pyoderma gangrenosum is a severe manifestation
b. Leukocytoclastic vasculitis is a characteristic histo-
logical finding
c. The condition rarely progresses to systemic PAN
d. It is the commonest cause of vasculitis involving
the skin in children
4. Regarding KD, which of the following is correct?
a. IV-Ig can be effective if administered later than
10 days after disease onset
b. Only coronary arteries are affected
c. Acute glomerulonephritis is the usual renal
manifestation
d. The disease is unlikely unless all criteria are met
5. For KD, which of the following is false?
a. There is evidence for genetically determined sus-
ceptibility to the disease
b. Long-term endothelial dysfunction has been dem-
onstrated after the acute phase
c. Female patients with cardiac sequelae have a higher
mortality rate than male patients
d. There are data supporting an aetiological role for
superantigens
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